Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems Licenses Eukarion Compounds to Minerva, Names New CEO

NEW YORK (GenomeWeb News) — Proteome Systems has licensed its Eukarion portfolio of small-molecule drug compounds to Minerva Healthcare, which is developing treatments for dermatological and other diseases, Proteome Systems said last week. 
The company also said it has appointed Jenny Harry CEO, replacing Stephen Porges. Harry has been deputy CEO since 2005.
Under the terms of the Minerva agreement, Proteome Systems will receive $4 million upfront and will gain a 10 percent stake in Minerva, as well as a milestone payment for clinical development and 12 percent of royalties from product sales.
Minerva is a new venture founded by Athena Diagnostics, Ivax Pharmaceuticals, and Impax Pharmaceuticals, Proteome Systems said.
Proteome Systems said the license is subject to Minerva’s ability to raise its initial capital.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.